**Core tip:** Endoscopic hemostasis represents the cornerstone of upper gastrointestinal bleeding treatment, and several scores have been developed for the prediction of rebleeding. This is a first study on Croatian patients to include over 1000 participants with peptic ulcer bleeding, and the aim was to compare three scores (Glasgow Blatchford score, Rockall score and Baylor bleeding score) in the prediction of peptic ulcer bleeding treatment outcome, including need for hospital-based intervention or 30-d mortality, 30-d rebleeding rate, 30-d mortality rate, and needs for surgical intervention and blood transfusion, and to find optimal cutoff values that indicate high-risk patients.

INTRODUCTION
============

Upper gastrointestinal bleeding (UGIB) is a common medical emergency. Incidence rates of UGIB demonstrate variations ranging from 48 to 160 cases per 100000 population\[[@B1]\]. The most common causes of acute UGIB are non-variceal, where 28% to 59% are caused by peptic ulcer bleeding (PUB)\[[@B1]-[@B3]\]. Endoscopic hemostasis represents the cornerstone of UGIB treatment, and several scores have been developed for the prediction of clinical intervention (*i.e*. Rockall score (RS), Glasgow-Blatchford score (GBS), Baylor bleeding score (BBS), Cedars-Sinai Medical Center predictive index, Almela score, AIMS65 score)\[[@B4]-[@B14]\]. The recently published American College of Gastroenterology practice guidelines on the management of patients with ulcer bleeding recommend risk assessment in all patients in order to stratify them into high or low risk categories, since it may assist in initial decisions regarding the timing of endoscopy, time of discharge, and level of care\[[@B15]\].

The GBS is a pre-endoscopic score and contains the following parameters: initial hemoglobin levels, urea, blood pressure, pulse, known syncope, melena, and liver or cardiac failure. Each variable has an appointed numeric value and the maximal number of points is 23 (Table [1](#T1){ref-type="table"}). The GBS was designed to predict lower risk bleeds, and a GBS value of 1 or lower indicates very low risk category\[[@B8],[@B9]\]. The most commonly used RS consists of a pre-endoscopic evaluation part, which includes age, signs of shock and comorbidities, along with an endoscopic part, which evaluates high-risk endoscopic characteristics as well (known as the post-endoscopic RS) (Table [2](#T2){ref-type="table"}). Each variable is appointed a numeric value and every value \> 2 indicates a high-risk patient\[[@B7]\]. The maximal pre-endoscopic RS value is 7, and the maximal post-endoscopic value is 11. The post-endoscopic RS can be calculated if bleeding is diagnosed and evaluated with upper endoscopy\[[@B7],[@B16],[@B17]\]. The BBS contains a pre-endoscopic evaluation part, which includes age, severity and duration of associated diseases, along with a post-endoscopic part, which evaluates the position and type of fresh bleeding (Table [3](#T3){ref-type="table"}). The maximal pre-endoscopic BBS is 15, and the maximum total (pre-endoscopic and post-endoscopic) BBS is 24\[[@B18]\].

###### 

Glasgow-Blatchford score

                                  **Assigned score**   
  ------------------------------- -------------------- ---
  Blood urea, mmol/L              6.5 -7.9             2
  8.0-9.9                         3                    
  10.0-24.9                       4                    
  ≥ 25                            6                    
  Hemoglobin for men, g/dL        12 -12.9             1
  10-11.9                         3                    
  \< 10                           6                    
  Hemoglobin for women, g/dL      10-11.9              1
  \< 10                           6                    
  Systolic blood pressure, mmHg   100-109              1
                                  90-99                2
                                  \< 90                3
  Other markers                   Pulse ≥ 100          1
  Melena                          1                    
  Syncope                         2                    
  Hepatic disease                 2                    
  Cardiac failure                 2                    

###### 

Rockall score

                                                                     **Points**                                                                                                                                                                                                              
  ---------------------------------- ------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------- --
  Pre-endoscopic score               Age, yr                         \< 60                                                                        60-79                                                                              ≥ 80                                                    
  Shock                              Systolic blood pressure ≥ 100   Systolic blood pressure ≥ 100 mmHg                                           Systolic blood pressure \< 100                                                                                                             
                                     Pulse ≥ 100/min                                                                                                                                                                                                                                         
  Pulse \< 100/min                                                                                                                                                                                                                                                                           
  Comorbidity                        No major comorbidity                                                                                         Cardiac failure, ischemic heart disease, any major comorbidity                     Renal failure, liver failure, disseminated malignancy   
  Post-endoscopic score              Diagnosis                       Mallory-Weiss tear, no lesion identified and no signs of recent hemorrhage   All other diagnosis                                                                Malignancy of upper gastrointestinal tract              
  Major signs of recent hemorrhage   None or dark spot only                                                                                       Blood in upper gastrointestinal tract, adherent clot, visible or spurting vessel                                                           

###### 

Baylor bleeding score

  **Assigned score**   **Age, yr**      **No. of parallel illnesses**   **Severity of illnesses**   **Site of bleeding**   **Stigmata of bleeding**
  -------------------- ---------------- ------------------------------- --------------------------- ---------------------- --------------------------
  0                    \< 30            0                                                                                  
  1                    30-49            1 or 2                                                                             Clot
  2                    50-59                                                                                               
  3                    60-69                                                                                               Visible vessel
  4                                     3 or 4                          Chronic                     Posterior wall bulb    
  5                    ≥ 70             ≥ 5                             Acute                                              Active bleeding
  Score                Pre-endoscopic   Post-endoscopic                                                                    

The RS was primarily developed to predict mortality and the GBS to evaluate need for clinical intervention\[[@B6]-[@B14]\]. Secondarily, they can be applied to asses rebleeding risk. The BBS was primarily developed to identify patients at high risk for rebleeding after endoscopic hemostasis\[[@B6],[@B16]\]. In previous studies, the GBS has been shown to be better than the pre-endoscopic and post-endoscopic RS in predicting the need for hospital-based intervention in patients with UGIB\[[@B6],[@B13],[@B19]\]. On the other hand, the RS appeared to be better at predicting mortality after rebleeding, contributing to more accurate diagnostics and shorter hospital stay\[[@B7],[@B13],[@B14]\]. Recent studies have shown that early endoscopy (within 24 h of presentation) is performed in only half of patients with UGIB, demonstrating the need for reliable and accurate pre-endoscopic risk assessment\[[@B6]-[@B15],[@B20]-[@B25]\].

This is the first prospective study in Croatia to include over 1000 patients with PUB, and the aim was to compare the GBS, pre-endoscopic RS and pre-endoscopic BBS, as well as the post-endoscopic RS and post-endoscopic BBS, in the prediction of PUB treatment outcome, need for hospital-based intervention (endoscopic treatment, transfusion, surgery intervention) or 30-d mortality, including 30-d rebleeding rate, 30-d mortality rate, and needs for surgical intervention and blood transfusion, and to find optimal cutoff values that indicate high-risk patients.

MATERIALS AND METHODS
=====================

This prospective study was conducted in the University Hospital Center "Sestre Milosrdnice" that covers a population of approximately 300000 in the City of Zagreb, Croatia. All patients presenting to the Emergency Unit between January 2008 and December 2013 with hematemesis, melena, hematochezia, or blood admixture upon nasogastric insertion were considered for study enrolment. If initial work-up indicated the need for hospitalization, patients were admitted to the Interventional Gastroenterology Unit.

Upper gastrointestinal endoscopy was performed in all patients within 24 h of admission. Only patients with gastric and/or duodenal ulcers, or an ulcer at the site of gastro-enteric anastomosis found during emergency endoscopy, without any other possible cause of bleeding were included in the study. All patients with high-risk ulcer stigmata and patients selected depending on clinical judgment received high-dose acid suppression therapy (pantoprazole or esomeprazole 80 mg as an intravenous bolus, followed by 40 mg intravenously 2 times daily or 200 mg daily in the form of continuous infusion for at least 48 h followed by 40 mg daily by mouth). The institution's ethics committee approved the study. Data was prospectively entered into a database, with patient details stored in a depersonalized manner to protect patient confidentiality.

Data collection
---------------

The following data were collected for each patient: demographic data, history of ulcer or liver disease, coexisting and past illnesses, medication use, clinical characteristics of the bleeding episode, laboratory results, endoscopic diagnosis including stigmata of ongoing or recent hemorrhage, endoscopic intervention, medical treatment, rebleeding, surgical therapy, duration of hospitalization and cause of death. The grading of overall health and co-morbidity was performed according to the American Society of Anesthesiology (ASA) classification (grade 1, normal healthy patients; grade 2, mild systemic illness; grade 3, severe but incapacitating systemic illness; grade 4, life-threatening illness). Stigmata of hemorrhage were defined according to the Forrest classification (Forrest Ia, spurting bleeding; Forrest Ib, oozing bleeding; Forrest IIa, non-bleeding visible vessel; Forrest IIb, adherent clot; Forrest IIc, hematin on ulcer base; Forrest III, clean ulcer base).

Shock was defined as syncope or signs of shock at physical examination, including systolic blood pressure less than 100 mmHg and pulse rate more than 100 beats/min.

Post-hemorrhagic anemia was corrected with red blood cell transfusion (2 units, approximately 500 mL) at a hemoglobin threshold of 70-80 g/L.

All patients diagnosed with PUB and high-risk stigmata underwent initial hemostasis (injection of dilute epinephrine into and around the bleeding point, positioning of clips or thermal coagulation, or both, but never epinephrine alone). Two biopsy specimens were obtained from the gastric antrum and body in all patients and the presence of *Helicobacter pylori (H. pylori)* infection was assessed by histopathological examination of the specimens using hematoxylin-eosin (HE) stain.

All patients with negative histology for *H. pylori* at index endoscopy had a control endoscopy with repeating biopsy samples, or urea breath test (UBT), performed 2 wk after proton-pump inhibitor treatment was discontinued. Patients in whom the described protocol was not followed were excluded from the study about *H. pylori* infection.

Rebleeding was defined as one or more signs of recurrent bleeding, including fresh hematemesis or melena, hematochezia, aspiration of fresh blood *via* nasogastric tube, instability of vital signs, and reduction of hemoglobin levels by 2 g/dL or more, occurring 24-h after the primary bleeding was stopped.

For all patients with gastric ulcer in whom recurrent bleeding was not observed, control endoscopy was performed 4-5 d after initial hemostasis and biopsy specimens were obtained from the margins and base of gastric ulcers to exclude malignancy. Control endoscopy with histology had been planned to be performed in all patients with gastric ulcer.

Documented clinical outcomes were: need for hospital-based intervention or 30-d mortality, 30-d rebleeding, 30-d mortality and interventions (transfer to the Department of Surgery and the need for blood transfusion).

The collected data was used to calculate the GBS score, as well as the pre-endoscopic RS and pre-endoscopic BBS for each patient presenting with UGIB. The post-endoscopic RS and BBS were calculated if bleeding from gastric, duodenal or gastro-enteric ulcers was endoscopically diagnosed. Methods for calculating the GBS, RS and BBS were as previously described. Pre-endoscopic and post-endoscopic scores were separately evaluated.

Statistical analysis
--------------------

The Mann-Whitney *U*-test and Kruskal-Wallis analysis of variance test were used to analyze differences in quantitative data. The discriminative ability of the scoring systems to predict outcomes was evaluated by receiver operating characteristics curves (ROC) with 95%CI. The areas under ROC (AUROC) curves were compared using the method of Delong et al\[[@B26]\] (1988) for the calculation of the standard error of the Area Under the Curve (AUC) and of the difference between two AUCs. The optimal thresholds of the GBS, RS and BBS for the prediction of rebleeding, death, and needs for blood transfusion and/or surgical intervention were identified as the threshold associated with the highest Youden index\[[@B27]\]. A two-tailed significance level of 5% was used in all comparisons. All analyses were performed using a statistical package MedCalc for Windows, version 15.8 (MedCalc Software, Ostend, Belgium).

RESULTS
=======

The analysis included 2643 patients with UGIB, of that 2326 (88%) patients had non-variceal bleeding, 225 (8.5%) had variceal bleeding, and 92 (3.5%) had an unidentified cause of bleeding.

From 2418 patients with non-variceal bleeding, 41.9% (1012) had PUB; specifically, the cause of bleeding in 49% (496) was gastric ulcer, in 47% (476) duodenal ulcer, in 2.4% (24) both gastric and duodenal ulcer, and in 1.6% (16) gastro-enteric anastomosis ulcer. Endoscopic treatment was required in 58% of patients with ulcer bleeding, and in 57.3% hemostasis was achieved with hemoclips or with combination hemoclips/diluted epinephrine. The rate of rebleeding was 9.4%, and in patients that were on anticoagulant therapy the rebleeding rate was 14.8% (*P* = 0.245), which was not statistically significant. In total, 5.4% of the patients were transferred to the Department of Surgery. The 30-d mortality was 5.2% and the median length of hospitalization was 6 d. Transfusion of red blood cells was performed in 49% of patients. Patients were predominantly men (median age 65.3). In 52% of patients, high-risk ulcers were verified (Forrest Ia-IIb), 11% of the patients presented with shock, and moderate to severe comorbidity was found in 58%. Furthermore, 28.1% patients with peptic ulcer had been taking nonsteroidal anti-inflammatory drugs, 20% acetylsalicylic acid, 3.1% antiplatelet medication and 6% anticoagulant therapy.

*H. pylori* testing was performed in 760 (75.1%) patients, of which 324 (42.6%) tested positive. Table [4](#T4){ref-type="table"} shows the patient characteristics and clinical outcomes.

###### 

Patient characteristics and clinical outcomes

  ------------------------------------- -------------------
  Age                                   
  Median, yr                            65.3 (20-100)
  Sex                                   
  Male/Female                           638 (63)/374 (37)
  Findings at endoscopy                 
  Gastric ulcers                        496 (49)
  Duodenal ulcers                       476 (47)
  Gastric and duodenal ulcers           24 (2.4)
  Ulcer on gastro-enteric anastomosis   16 (1.6)
  High-risk ulcers (Forrest Ia-IIb)     526 (52)
  Forrest Ia                            61 (6)
  Forrest Ib                            111 (11)
  Forrest IIa                           212 (21)
  Forrest IIb                           142 (14)
  Low- risk ulcers (Forrest IIc-III)    486 (48)
  Forrest IIc                           172 (17)
  Forrest III                           314 (31)
  Hemodynamic shock                     111 (11)
  Comorbidity                           
  Ischemic and valvular heart disease   213 (21.5)
  Liver disease                         172 (17)
  Renal failure                         111 (11)
  Any malignancy                        131 (12.9)
  Comorbidity (ASA class)               
  ASA I                                 142 (14)
  ASA II                                283 (28)
  ASA III-IV                            587 (58)
  *H. pylori*                           
  Tested                                760 (75.1)
  *H. pylori*-positive                  324 (42.6)
  Drugs                                 
  Without previous therapy              433 (42.8)
  NSAIDs                                284 (28.1)
  Acetylsalicylic acid                  203 (20)
  Antiplatelet therapy                  31 (3.1)
  Anticoagulant therapy                 41 (4)
  NOAC                                  20 (2)
  Treatment                             
  Endoscopic therapy                    587 (58)
  Epinephrine                           213 (36.3)
  Hemoclips                             156 (26.6)
  Hemoclips + epinephrine               180 (30.7)
  Thermocoagulation                     26 (4.4)
  Thermocoagulation + epinephrine       12 (2)
  Repeated endoscopic therapy           71 (7)
  Blood transfusion required            496 (49)
  Red blood cell                        406 (40.1)
  Median (range), unit                  2.5 (1-16)
  Fresh frozen plasma                   81 (8)
  Median (range), unit                  2 (1-6)
  Platelet                              9 (0.9)
  Median (range), unit                  6 (4-8)
  Whole blood                           0 (0)
  Surgery                               55 (5.4)
  Outcome                               
  Rebleeding                            95 (9.4)
  Rebleeding (anticoag. and NOAC)       9 (14.8)
  30-d mortality                        53 (5.2)
  Median hospital stay, d               6 (0-45)
  ------------------------------------- -------------------

Data are presented as *n* (%) or mean (range). ASA: American society of anesthesiology; NOAC: New(er) oral anticoagulant; NSAIDs: Non-steroidal anti-inflammatory drugs.

Using ROC curve analysis we found that the GBS was clearly superior to pre-endoscopic RS and pre-endoscopic BBS, in predicting need for hospital-based intervention or 30-d mortality (AUROC 0.84 *vs* 0.57 *vs* 0.64 respectively) (Figure [1](#F1){ref-type="fig"}).

![Comparison of Glasgow-Blatchford score, pre-endoscopic Rockall score and pre-endoscopic Baylor bleeding score in predicting need for hospital-based intervention or 30-d mortality. AUROC \[0.83 (95%CI: 0.81-0.86)\] *vs* \[0.63 (95%CI: 0.59-0.68)\] *vs* \[0.57 (95%CI: 0.53-0.61)\]. GBS: Glasgow-Blatchford score; BBS: Baylor bleeding score; RS: Rockall score.](WJG-23-7450-g001){#F1}

The cutoff value that maximized the sum of the sensitivity and specificity for predicting 30-d mortality for the pre-endoscopic RS was 4 (sensitivity 0.63, specificity 0.85, total 1.48), and 5 for the post-endoscopic RS (sensitivity 0.83, specificity 0.68, total 1.51).

Based on ROC analysis of sensitivity and specificity, the optimal cutoff value of the pre-endoscopic BBS for 30-d mortality was 8 (0.63 sensitivity, 0.58 specificity, total 1.21), and the optimal cutoff post-endoscopic BBS value for 30-d mortality was 9 (0.88 sensitivity, 0.40 specificity, total 1.28).

When assessing scores for the prediction of lethal outcome in patients with PUB, the pre-endoscopic RS was superior compared to the GBS and the pre-endoscopic BBS (AUROC 0.82 *vs* 0.67 *vs* 0.63, respectively) (Figure [2A](#F2){ref-type="fig"}).

![Comparison of the Glasgow-Blatchford score, pre-endoscopic Rockall score and pre-endoscopic Baylor bleeding score for the prediction of death, recurrent bleeding, transfusion or surgical intervention. A: AUROC \[0.67 (95%CI: 0.64-0.70)\] *vs* \[0.82 (95%CI: 0.79-0.84)\] *vs* \[0.63 (95%CI: 0.60-0.66)\]; B: AUROC \[0.75 (95%CI: 0.72-0.78)\] *vs* \[0.61 (95%CI: 0.57-0.64)\] *vs* \[0.52 (95%CI: 0.49- 0.56)\]; C: AUROC \[0.83 (95%CI: 0.80-0.85)\] *vs* \[0.63 (95%CI: 0.59-0.66)\] *vs* \[0.58 (95%CI: 0.55-0.62)\]; D: AUROC \[0.82 (95%CI: 0.79-0.84)\] *vs* \[0.63 (95%CI: 0.60-0.66)\] *vs* \[0.52 (95%CI: 0.48-0.55)\]. GBS: Glasgow-Blatchford score; BBS: Baylor bleeding score; RS: Rockall score.](WJG-23-7450-g002){#F2}

Based on the ROC analysis of sensitivity and specificity, the optimal cutoff GBS value for 30-d mortality was 12 (0.49 sensitivity, 0.75 specificity, total 1.24), for rebleeding 11 (0.71 sensitivity, 0.67 specificity, total 1.38), for blood transfusion 9 (0.71 sensitivity, 0.67 specificity, total 1.38) and for surgery 12 (0.71 sensitivity, 0.76 specificity, total 1.47).

The GBS score was superior to the pre-endoscopic RS and BBS in the prediction of rebleeding (AUROC 0.75 *vs* 0.61 *vs* 0.52) (Figure [2B](#F2){ref-type="fig"}).

The GBS score was superior to the pre-endoscopic RS and BBS in predicting the need for blood transfusion (AUROC 0.83 *vs* 0.63 *vs* 0.59, respectively) (Figure [2C](#F2){ref-type="fig"}) and transfer to the Department of Surgery (AUROC 0.82 *vs* 0.63 *vs* 0.52, respectively) (Figure [2D](#F2){ref-type="fig"}). Also, the post-endoscopic RS was superior to the post-endoscopic BBS (AUROC 0.82 *vs* 0.69) in the prediction of lethal outcome (Figure [3A](#F3){ref-type="fig"}).

![Comparison of the post-endoscopic Rockall score and post-endoscopic Baylor bleeding score for the prediction of death recurrent bleeding, transfusion or surgical intervention. AUROC: \[0.82 (95%CI: 0.79-0.84)\] *vs* \[0.69 (95%CI: 0.65-0.72)\]; B: AUROC \[0.70 (95%CI: 0.67-0.73)\] *vs* \[0.73 (95%CI: 0.70-0.76)\]; C: AUROC \[0.66 (95%CI: 0.62-0.70)\] *vs* \[0.65 (95%CI: 0.61-0.69)\]; D: AUROC \[0.68 (95%CI: 0.65-0.71)\] *vs* \[0.74 (95%CI: 0.71-0.77)\]. BBS: Baylor bleeding score; RS: Rockall score.](WJG-23-7450-g003){#F3}

There was no significant difference between the post-endoscopic RS and BBS in the prediction of rebleeding (AUROC 0.70 *vs* 0.73) (Figure [3B](#F3){ref-type="fig"}).

The rebleeding cutoff point that maximized the sum of the sensitivity and specificity for the pre-endoscopic BBS was 3 (sensitivity 0.90, specificity 0.19, total 1.09), and 11 for the post-endoscopic BBS (sensitivity 0.66, specificity 0.76, total 1.42).

There was no significant difference between the post-endoscopic RS and BBS in predicting the need for blood transfusion (AUROC 0.68 *vs* 0.71) (Figure [3C](#F3){ref-type="fig"}) and transfer to the Department of Surgery (AUROC 0.68 *vs* 0.74) (Figure [3D](#F3){ref-type="fig"}).

DISCUSSION
==========

UGIB is the most important cause of emergency gastroenterological admissions and the most frequent condition requiring emergency endoscopy\[[@B1]\]. The most common causes of acute UGIB are non-variceal, of which 30% to 60% are attributed to PUB\[[@B28]\]. In our study, 42% of all non-variceal bleeding was caused by PUB. In order to assess the adequate timing of endoscopy and selection of patients for hospital admission, several scoring systems for risk estimation have been developed. With the array of available scoring systems, it is often difficult to select the ideal scoring system for a particular patient or clinical outcome of interest. Therefore, in this study, we compared the performance of these scoring systems in the risk assessment of various clinical outcomes.

Our study showed that the GBS is superior to the pre-endoscopic RS and BBS in predicting need for hospital-based intervention or 30-d mortality. This is in concordance with the results from a study by Laursen\[[@B22]\] and a study by Bryant et al\[[@B19]\]. Our study also showed that the GBS is superior to the pre-endoscopic RS and BBS in predicting peptic ulcer re-bleeding. An explanation for why the GBS best predicts peptic ulcer rebleeding is that it incorporates hemoglobin and serum urea values. Serum urea is a good biochemical marker for UGIB because it rises rapidly when there is catabolism of isoleucine-poor hemoglobin\[[@B8],[@B29]\]. The maximal level of hemoglobin and urea account for half of the maximal sum of points in the GBS score.

Our study showed that there is no significant difference between the post-endoscopic BBS and post-endoscopic RS in predicting peptic ulcer rebleeding. This is in concordance with the results from a study by Laursen et al\[[@B6]\]. Similar data was published by Italian and Dutch researchers, who also found low values under the ROC curve \[(0.59-0.68) and 0.61\] and concluded that the RS is not appropriate for prediction of rebleeding\[[@B16],[@B30]\].

Our study showed that the GBS is superior to the pre-endoscopic RS and pre-endoscopic BBS in predicting the needs for blood transfusion and/or transfer to the Department of Surgery. The ROC curve for GBS rebleeding was similar to the GBS ROC curve for blood transfusion requirement and transfer to the Department of Surgery because peptic ulcer rebleeding is the main cause of blood transfusion requirement and need for surgical intervention. Bryant et al\[[@B19]\] published similar data.

Our study showed that the pre-endoscopic RS was superior to the GBS and pre-endoscopic BBS in predicting mortality. The RS best predicted fatal outcome because it incorporated the majority of risk factors (age, shock, moderate to severe co-morbidities and high-risk endoscopic signs for rebleeding), which was valuable in a multivariate analysis of risk for fatal outcome\[[@B7],[@B13],[@B30],[@B31]\]. Our study showed that the post-endoscopic RS is superior to the post-endoscopic BBS in predicting lethal outcome in patients with PUB. Laursen\[[@B22]\] did not find any significant difference in AUROC among post-endoscopic BBS and post-endoscopic RS.

According to studies by Hyett et al\[[@B14]\] and Bryant et al\[[@B19]\], the GBS cutoff points for high-risk of lethal outcome and rebleeding were ≥ 10 and ≥ 12, respectively. In a recent retrospective study, Lim et al\[[@B32]\] suggested urgent endoscopy in the first 13 h after clinical presentation in high-risk patients with GBS \> 12, in the first 24 h in patients with GBS \> 7 and for patients with GBS values between 4 and 7 urgent endoscopy in the first 24 h is recommended, but not necessary.

Our cutoff points for high-risk of rebleeding and lethal outcome in PUB patients are significantly different in comparison with original research papers (GBS ≥ 2, pre-endoscopic BBS \> 5, post-endoscopic BBS ≥ 10, post-endoscopic RS ≥ 4), which all refer to UGIB\[[@B6]-[@B9],[@B13],[@B14]\]. An explanation for this could be that the original series included an unselected group of patients with UGIB, with a significant proportion of patients with a low-risk of death, recurrent bleeding, and needs for blood transfusion and/or surgical intervention. These were patients that presented with low-risk bleeding ulcers (Forrest IIc and Forrest III), Mallory-Weiss syndrome, ulcerative esophagitis, angiodysplasia and portal hypertensive gastropathy.

When considering possible limitations of our study, there is always a certain level of subjectivity in the endoscopic classification of ulcers and variation in endoscopic treatment. Furthermore, our study had a relatively short follow-up period of 30 d.

By comparing the ROC curves of the aforementioned pre-endoscopic scores, the RS proved to be the best score for predicting lethal outcome. The post-endoscopic RS was also better than the post-endoscopic BBS in predicting lethal outcome in patients with PUB. On the other hand, among the three pre-endoscopic scores, the GBS best predicted need for hospital-based intervention or 30-d mortality, rebleeding, and needs for blood transfusion and/or surgical intervention.
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